文献速递淋巴瘤

靶向IRAK4可破坏慢性淋巴细胞白血病炎症通路并延缓肿瘤发展

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2019-06-13

研究探讨TLR激活及IRAK4竞争性抑制剂ND2158在慢性淋巴细胞白血病(CLL)中的作用。体外实验显示ND2158以剂量依赖方式优先杀伤CLL细胞,并降低NF-κB和STAT3信号、细胞因子分泌、增殖与迁移;在Eµ-TCL1小鼠模型中ND2158延缓肿瘤进展并调节髓系和T细胞活性。

要点

  • ND2158以剂量依赖方式优先杀伤CLL细胞。
  • ND2158降低MYD88突变及未突变CLL原代细胞的NF-κB和STAT3信号、细胞因子分泌、增殖与迁移。
  • Eµ-TCL1小鼠模型中ND2158延缓肿瘤进展并调节髓系和T细胞活性。

核心结论

  • TLR信号在CLL发展中具有重要性,IRAK4可能是CLL的治疗靶点。

研究设计与样本

  • 体外研究使用IRAK4竞争性抑制剂ND2158处理CLL原代细胞,并在Eµ-TCL1过继转移CLL小鼠模型中进行体内研究。

主要发现

  • ND2158以剂量依赖方式优先杀伤CLL细胞。
  • ND2158降低MYD88突变和未突变CLL原代细胞的NF-κB与STAT3信号、细胞因子分泌、增殖和迁移。
  • 在Eµ-TCL1过继转移小鼠模型中,ND2158延缓肿瘤进展并调节髓系和T细胞活性。

关键数值与推荐

  • 约3%的CLL患者携带MYD88激活突变。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in Toll-like receptor (TLR) signal transduction and innate immune responses. Recruitment and subsequent activation of IRAK4 upon TLR stimulation is mediated by the myeloid differentiation primary response 88 (MYD88) adaptor protein. Around 3% of chronic lymphocytic leukemia (CLL) patients have activating mutations of MYD88, a driver mutation in this disease. Here, we studied the effects of TLR activation and the pharmacological inhibition of IRAK4 with ND2158, an IRAK4 competitive inhibitor, as a therapeutic approach in CLL. Our in vitro studies demonstrated that ND2158 preferentially killed CLL cells in a dose-dependent manner. We further observed a decrease in NF-κB and STAT3 signaling, cytokine secretion, proliferation and migration of primary CLL cells from MYD88-mutated and -unmutated cases. In the Eµ-TCL1 adoptive transfer mouse model of CLL, ND2158 delayed tumor progression and modulated the activity of myeloid and T cells. Our findings show the importance of TLR signaling in CLL development and suggest IRAK4 as a therapeutic target for this disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Giménez N, Schulz R, Higashi M, et al. Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia. 2019. PMID: 31197259. doi:10.1038/s41375-019-0507-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。